Tag:
CP-4126
Latest Headlines
Latest Headlines
Clovis extends deal-making spree with $206M Asian pact
Flush with cash from its $146 million A round last year, Clovis Oncology is ramping up a cancer drug pact it has with Norway's Clavis Pharma, adding $10 million in an upfront fee and $195M in
Clavis Pharma gets orphan drug status, new CEO
Clavis Pharma announced today that the FDA has granted its intravenous pancreatic cancer treatment CP-4126 orphan drug designation. Clavis signed a $380 million development and commercialization deal
Clavis inks $380M deal with Clovis Oncology
Norway's Clavis Pharma has reason to celebrate this morning. The developer has inked a $380 million deal with US-based Clovis Oncology, sending shares up as much as 60 percent, according to Reuters.
